ACUR:OTC-Acura Pharmaceuticals, Inc (USD)

COMMON STOCK | Drug Manufacturers-Specialty & Generic | OTC

Last Closing Price

USD 0.35

Change

-0.01 (-2.78)%

Market Cap

USD 7.79M

Volume

0.02M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Acura Pharmaceuticals, Inc., a specialty pharmaceutical company, engages in the research, development, and commercialization of technologies and products to address safe use of medications in the United States. It offers Oxaydo tablets, a Schedule II narcotic indicated for the management of acute and chronic moderate to severe pain; and Nexafed products, which are pseudoephedrine and acetaminophen tablets that are used as nasal decongestants in various non-prescription and prescription cold, sinus, and allergy products. The company has six additional opioid products in various stages of formulation development. Acura Pharmaceuticals, Inc. has collaboration and license agreements with Egalet US, Inc.; and Egalet Ltd. to manufacture and commercialize Oxaydo products worldwide; and development and commercialization agreement with Abuse Deterrent Pharma, LLC to develop LTX-03, an immediate-release tablets utilizing LIMITx technology. The company was founded in 1935 and is based in Palatine, Illinois.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2021-03-04 )

Largest Industry Peers for Drug Manufacturers-Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
BAYP Bayport International Holdings..

-6.40 (-44.26%)

USD196.07B N/A N/A
MKKGY MERCK Kommanditgesellschaft au..

-0.16 (-0.50%)

USD69.14B 30.84 17.34
MKGAF MERCK Kommanditgesellschaft au..

+1.42 (+0.90%)

USD68.18B 30.61 17.34
TKPHF Takeda Pharmaceutical Company ..

+0.61 (+1.78%)

USD56.00B 20.90 0.10
ESALY Eisai Co., Ltd

-1.75 (-2.53%)

USD19.72B 33.19 0.13
ESALF Eisai Co., Ltd

N/A

USD19.67B 34.36 0.13
SFOSF Shanghai Fosun Pharmaceutical ..

N/A

USD16.50B 27.22 3.30
SGIOY Shionogi & Co., Ltd

-0.48 (-3.69%)

USD15.86B 1.97 0.07
SGIOF Shionogi & Co., Ltd

-2.11 (-4.00%)

USD15.83B 15.96 0.07
TEVJF Teva Pharmaceutical Industries..

-0.45 (-4.29%)

USD11.83B 900.00 16.02

ETFs Containing ACUR

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers-Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 66.67% 57% F 76% C
Dividend Return N/A N/A N/A N/A N/A
Total Return 66.67% 57% F 76% C
Trailing 12 Months  
Capital Gain 9.37% 35% F 40% F
Dividend Return N/A N/A N/A N/A N/A
Total Return 9.37% 35% F 39% F
Trailing 5 Years  
Capital Gain -83.17% 16% F 9% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -83.17% 16% F 8% F
Average Annual (5 Year Horizon)  
Capital Gain -16.17% 31% F 12% F
Dividend Return N/A N/A N/A N/A N/A
Total Return -16.17% 30% F 11% F
Risk Return Profile  
Volatility (Standard Deviation) 59.83% 56% F 39% F
Risk Adjusted Return -27.03% 32% F 23% F
Market Capitalization 7.79M 35% F 30% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 87%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers-Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 7.00 55% F 76% C
Price/Book Ratio N/A N/A N/A N/A N/A
Price / Cash Flow Ratio -12.61 76% C 81% B-
EV/EBITDA 15.70 27% F 24% F
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital -77.71% 21% F 10% F
Return on Assets 8.31% 93% A 93% A
Debt to Equity Ratio -126.56% 91% A- 96% A
Technical Ratios  
Short Ratio 0.73 50% F 55% F
Short Percent 1.20% 29% F 47% F
Beta 0.70 58% F 58% F
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

Superior Earnings Growth

This stock has shown top quartile earnings growth in the previous 5 years compared to its sector.

High Gross Profit to Asset Ratio

This stock is in the top quartile compared to its peers on Gross Profit to Asset Ratio. This is a popular measure among value investors for showing superior returns in the long run.

What to not like:
Low market capitalization

This is among the smaller entities in its sectors with below median market capitalization. That may make it less stable in the long run unless it has a unique technology or market which can help it grow or get acquired in future.

Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Negative cashflow

The company had negative total cash flow in the most recent four quarters.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.